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ABSTRACT
Background: Pre‑eclampsia is a multisystemic disorder complicating pregnancy. It is associated with a significant burden 
on maternal and perinatal health, especially when complicated by coagulation abnormalities.
Objective: The objective of the study was to determine the level of thrombocytopenia that predicts a risk of abnormalities 
of coagulation indices in severe preeclampsia and eclampsia.
Materials and Methods: Haemostatic factors including platelet count, prothrombin time (PT), activated partial thromboplastin 
time (APTT) and plasma fibrinogen were done for a cohort of 90 patients with severe preeclampsia and eclampsia at the 
Department of Obstetrics and Gynaecology, University of Benin Teaching Hospital, Benin City. Their demographic and 
laboratory data were analysed using the Statistical Package for Social Sciences version 20.0 and GraphPad InStat 3 software.
Results: Twenty‑one (23.3%) of the 90 patients had eclampsia. Mean age was 29.78 ± 4.7 years, parity was 2.54 ± 1.6 
and gestational age was 36.14 ± 2.9 weeks. Thrombocytopenia was found in 13 (14.4%) patients, whereas biochemical 
coagulopathy was found in 6 (6.7%) patients. Thrombocytopenia was 43% more likely with eclampsia than severe 
preeclampsia (47.6% vs 4.3, P = 0.001). Abnormal PT, APTT and plasma fibrinogen were more likely with platelet count 
below 80000 cell/µl (P = 0.046, P = 0.014 and P = 0.001, respectively). Eclampsia complicated with thrombocytopenia was 
associated with the most severe biochemical coagulopathy.
Conclusion: Thrombocytopenia frequently complicates eclampsia more than severe preeclampsia at platelet count levels 
below 80000 cell/µl. This level is discriminatory for biochemical coagulopathy, and it should prompt coagulation studies and 
warrant clinical vigilance.
Key words: Coagulopathy; eclampsia; platelet counts; severe preeclampsia; thrombocytopenia; University of Benin Teaching 
Hospital (UBTH).
Introduction
Coagulopathy results from an imbalance between 
the coagulation and fibrinolytic activities such that in 
hypercoagulable states, such as preeclampsia, activation of 
the thrombotic system leads to the development of multiple 
thrombi and rapid consumption of platelets, prothrombin, 
fibrinogen and coagulation factors. Coagulation failure is one 
of the most dreaded complications of severe preeclampsia 
and eclampsia. Its evolution significantly increases the toll of 
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the disease. Coagulopathy mainly develops as a component of 
the primary disease but may also arise from its complications 
such as intrauterine fetal death, abruptio placentae or 
primary postpartum haemorrhage. Coagulopathy may affect 
up to 15% of severe preeclampsia cases, and is believed to 
account for approximately 15% of maternal deaths from the 
condition.[1‑5]
Routine tests used to assess decompensated disseminated 
intravascular coagulopathy (DIC) have been considered 
to be of limited value in the preeclamptic and eclamptic 
population. It is advocated, especially in the developed world, 
that more sophisticated tests such as determinations of 
antithrombin III, thrombin‑antithrombin III complex, D‑dimer, 
factor VIII antigen/activity ratio and beta‑thromboglobulin 
be conducted to detect compensated coagulopathy 
in preeclampsia.[6‑9] Despite this, routine laboratory 
indicators of DIC have remained thrombocytopenia, 
prolonged prothrombin time, prolonged activated partial 
thromboplastin time and reduction in the concentration of 
fibrinogen. In low resource settings, where the means to 
achieve full scale coagulation profile assessment is either 
lacking or non‑existent, a greater reliance is placed on 
clinical observation for coagulopathy or the performance 
of bedside clotting time because this is rather inexpensive. 
However, the determination of prolonged clotting time will 
hardly be sufficient to hinge clinical decisions on. Hence, the 
use of platelet count appears to be more uniformly agreed 
as the basic investigation required for evaluating the risk of 
coagulopathy in severe preeclampsia.[10‑12]
The ease with which platelet count is done has led many 
authors to advocate its use as a screening test to identify 
potential candidates for further evaluation of coagulopathy. 
In this regard, platelet count can be assessed routinely for 
all patients with severe preeclampsia, and the result to 
be interpreted based on a cut‑off value for considering a 
complete coagulation study to predict coagulation disorder. 
However, the level of platelet depletion that has clinical 
implication remains a matter of debate with some workers 
reporting levels as low as 50000 cell/µl without any significant 
adverse outcome,[13,14] while others insist that less than 
100,000 cell/µl warrants further evaluation.[12]
Platelet count is a rapid, simple and cheap means of 
assessing haemostatic status compared to a complete 
coagulation profile, and its usefulness in detecting 
early coagulation disorder in conditions such as severe 
preeclampsia and eclampsia is no longer in doubt. What is 
not immediately apparent is the extent to or the accuracy 
with which thrombocytopenia can be used as a pointer to 
coagulation failure in preeclampsia in our environment. 
This study, therefore, is aimed at determining the platelet 
count that predicts coagulopathy in patients with severe 
preeclampsia and eclampsia in University of Benin Teaching 
Hospital (UBTH), Benin City.
Materials and Methods
This prospective, self‑controlled cohort study was conducted 
in the Department of Obstetrics and Gynaecology, UBTH, Benin 
City, Edo State, Nigeria, between December 2010 and March 
2011, with the approval of the hospital’s Ethics and Research 
Committee. The participants were all patients admitted with 
a diagnosis of severe preeclampsia or eclampsia and billed for 
stabilisation and delivery according to our standardized Labour 
Ward protocol.[15] Informed consent was obtained individually 
from the patients or their relatives. Patients with intrauterine 
foetal death at presentation, known coagulation disorders 
such as the haemophilias, immune thrombocytopenic purpura, 
inherited thrombocytopenia and von Willebrand disease, 
abruptio placentae, acute or chronic liver disease such as 
hepatitis, thromboembolic disorders and other hypercoagulable 
states, such as sickle cell disease, were excluded from the study.
UBTH is a tertiary health care facility located in Edo 
State, which serves as a major referral center in Nigeria, 
attracting patients from at least three neighboring states 
of Kogi, Ondo and Delta. Patients are also referred from 
both government‑owned and private hospitals within Edo 
State. Within the hospital, the major portal of entry for 
pregnant women is the General Practice Clinic (GPC) from 
where they are referred to the Antenatal Clinic for booking, 
however in emergency situations, patients are admitted via 
the Emergency Unit of the Hospital to the Labor Ward. On 
an average, between 100 and 150 patients are booked for 
antenatal care every week in the hospital, while follow‑up 
attendance rate is between 250 and 500 patients per week. 
The delivery rate in the hospital in the last 5 years has been 
approximately 2700 per year, which gives an average monthly 
delivery rate of 225. The hospital has a total antenatal and 
postnatal bed capacity of 82 spaces, and 8 functioning 
delivery rooms in the Labor Ward. There are 2 operating 
theatres attached to the Labor Ward.
In this study, patients who had antenatal care in UBTH 
were referred to as ‘booked’ and those not registered in 
UBTH as ‘unbooked’. Preeclampsia is defined as gestational 
hypertension plus proteinuria of 300 mg or more in 24 hour 
urine sample collection or persistent proteinuria of at 
least 30 mg/dl (at least 1+ on dipstick) in random urine 
samples.[5] Eclampsia is defined as the onset of seizures 
and/or unexplained coma during pregnancy, intrapartum 
or postpartum period in patients with signs and symptoms 
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of pre‑eclampsia.[5] In this study, the diagnosis of eclampsia 
was entertained when the patient was admitted to the Labor 
Ward either in coma or after a seizure in association with 
clinical evidence of the syndrome of preeclampsia, without 
any other obvious cause of coma or seizure. Their clinical 
management comprised seizure prophylaxis, blood pressure 
control and fluid replacement, correction of electrolytes 
derangement, intrauterine resuscitation and delivery by the 
most expedient route.
Venous blood samples were obtained for bedside clotting 
time, electrolytes, urea and creatinine, liver function tests and 
full blood count, in addition to platelet count, prothrombin 
time (PT), activated partial thromboplastin time (APTT) 
and plasma fibrinogen level. Preparation and analysis of 
the blood samples for coagulation indices were carried 
out immediately in conjunction with our colleagues in the 
Haematology Department of the Hospital. Thrombocytopenia 
was defined as platelet count <100,000 cell/µl, prolonged 
PT as >16 seconds, prolonged APTT as >40 seconds, and 
hypofibrinogenemia as <2 g/dl. In this study, ‘biochemical 
coagulopathy’ was defined as the abnormality of at least one 
of these 3 coagulation parameters evaluated.
Sociodemographic and laboratory information obtained 
were documented in structured pro‑forma, and were used 
to generate a database for analysis. The data was subjected 
to statistical analysis with a personal computer using the 
Statistical Package for the Social Sciences version 20.0 (SPSS 
IBM Corp, Armonk, NY) and GraphPad InStat 3 (GraphPad 
Software Inc., San Diego, CA). Univariate analysis was 
conducted using Chi‑square test or Fisher’s Exact Test as 
appropriate. Cross tabulations were conducted to determine 
associations. P value of <0.05 was considered significant.
Results
Out of the 90 women recruited, 69 (76.7%) had severe 
preeclampsia and 21 (23.3%) had eclampsia whereas 13 
women of this cohort had thrombocytopenia. Hence, the 
frequency of thrombocytopenia was 14.4%. Six patients 
had abnormal coagulation indices giving a biochemical 
coagulopathy rate of 6.7%. The majority (65.6%) of the 
patients were unbooked, which included all the 21 (23.33%) 
eclamptics and 38 (42.22%) severe preeclamptics. Thus, 44.9% 
of those with severe preeclampsia were unbooked patients. 
The mean platelet count was 163,000 ± 72 cell/µl, mean 
PT was 14.04 ± 3.2 s, mean APTT was 33.97 ± 3.1 s and 
mean fibrinogen level was 3.23 ± 0.5 g/dl.
The mean maternal age was 29.78 ± 4.7 years (range: 19 
to 43), the mean parity was 2.54 ± 1.6 (range: 0 to 6), and 
the mean gestational age was 36.14 ± 2.9 weeks (range: 24 
to 41), with almost 90% presenting after 32 weeks [Table 1]. 
The maternal age, parity and gestational age were not 
significantly different between the preeclamptics and those 
with eclampsia. Similarly, thrombocytopenic patients did 
not differ in terms of age, parity and gestational age from 
the other patients with normal platelet count (P = 0.730, 
P = 0.136 and P = 0.772, respectively) [Table 1].
The mean platelet count of patients with thrombocytopenia 
was over two‑fold lower than patients with normal platelet 
count (82800 ± 12075 cell/µl vs 188,000 ± 64523; 
P = 0.001). Hypofibrinogenemia was found in 31% of the 
thrombocytopenic patients but not in those with normal 
values (P = 0.001). Similarly, prolonged PT and APTT 
were seen in 46% and 23%, respectively, only in association 
with thrombocytopenia (P = 0.001 and P = 0.001, 
respectively) [Table 2].
Table 1: Maternal demographic characteristics in relation to 
thrombocytopenia
Variables Thrombocytopenic Normal P
n=13 (%) n=77 (%)
Age (years)
≤19 1 (7.7) 4 (5.2) 0.730
20-35 11 (84.6) 60 (77.9)
>35 1 (7.7) 13 (16.9)
Parity
0 5 (38.5) 43 (55.8) 0.136
1-4 8 (61.5) 27 (35.1)
>4 - - 7 (9.1)
Gestational age (weeks)
20-32 1 (7.7) 11 (14.3) 0.772
33-36 5 (38.5) 33 (42.9)
≥37 7 (53.9) 33 (42.9)
Table 2: Frequency and severity of abnormal plasma fibrinogen, 
APTT and PT in relation to thrombocytopenia
Variables Thrombocytopenic Normal P
n=13 (%) n=77 (%)
Fibrinogen (g/dl) 2.54±0.76 3.54±0.25 0.001*
< 2.0 4 (30.8) 0 (0.0)
2.0-4.0 9 (69.2) 77 (100.0)
>4.0 0 (0.0) 0 (0.0)
APTT (second) 35.92±5.11 33.13±2.26 0.001*
<26 0 (0.0) 0 (0.0)
26-40 10 (76.9) 77 (100.0)
>40 3 (23.1) 0 (0.0)
PT (second) 17.31±5.63 12.52±1.22 0.001*
<11 0 (0.0) 0 (0.0)
11-16 7 (53.9) 77 (100.0)
>16 6 (46.2) 0 (0.0)
PT - Prothrombin time; APTT - Activated partial thromboplastin time; * - Statistically 
significant values 
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Thrombocytopenia above 80,000 cell/µl was associated 
with 15% risk of prolonged PT but not prolonged APTT 
or abnormal fibrinogen level. Platelet count between 
50000 and 80000 cell/µl was associated with 100% risk of 
abnormal PT and fibrinogen level and 75% risk of prolonged 
APTT (P = 0.046, P = 0.001 and P = 0.014, respectively). 
Thrombocytopenia below 50000 cell/µl was not found in this 
study [Table 3].
The occurrence of eclampsia increased the risk of 
coagulopathy. Patients with eclampsia were 43% more likely to 
have thrombocytopenia than those with severe preeclampsia 
(47.6% vs 4.3, RR 10.95, 95% CI 3.32 to 36.16; P = 0.001). 
The mean platelet count and mean fibrinogen level were 21% 
lower and 18% lower, respectively, in patients with eclampsia 
than in patients with severe preeclampsia (144,000 ± 78662 
cell/µl vs 182,000 ± 65846, P = 0.031; and 2.92 ± 0.78 g/dl vs 
3.54 ± 0.26, P = 0.001, respectively). Similarly, the mean PT 
and mean APTT in eclampsia were 20% and 5%, respectively, 
higher than in severe preeclampsia (15.57 ± 5.03s vs 
12.49 ± 1.16, P = 0.001; and 34.76 ± 4.18 s vs 33.16 ± 2.42, 
P = 0.030, respectively) [Table 4].
The combination of eclampsia and thrombocytopenia 
further increased the severity of biochemical coagulopathy. 
Mean fibrinogen level was 1.5‑fold higher in 10 eclamptics 
without thrombocytopenia than 11 eclamptics with 
thrombocytopenia (3.47 ± 0.25 g/dl vs 2.31 ± 0.69, 
P = 0.001). Again, the mean PT and APT T were 
1.5‑fold and 1.1‑fold, respectively, more prolonged in 
eclamptics with thrombocytopenia than those without 
thrombocytopenia (18.80 ± 5.59s vs 12.64 ± 1.57, 
P = 0.002; and 36.40 ± 5.52s vs 33.27 ± 1.56, P = 0.087, 
respectively) [Table 4].
Only one of the patients showed clinical features of 
coagulopathy and had abnormalities of all the coagulation 
parameters with a platelet count of 68000 cell/µl.
Discussion
Disseminated intravascular coagulopathy is among 
the leading causes of mortality in preeclampsia and 
eclampsia.[4,5] A high index of clinical suspicion coupled with 
early laboratory confirmation remains the primary approach 
in the execution of an effective preventive modality. The 
incidence of thrombocytopenia among the patients we 
studied was 14.4%. Biochemical coagulopathy was noted in 
6.7%. Majority of the patients were unbooked, younger than 
35 years and at advanced gestational ages. Eclampsia was 
significantly associated with unbooked status and a higher 
risk of coagulopathy than severe preeclampsia. The risk of 
hypofibrinogenemia, prolonged PT and prolonged APTT 
increased with worsening thrombocytopenia.
The higher contribution of the unbooked patients to our 
population of severe preeclamptics and eclamptics is 
consistent with reports of other studies,[16,17] This observation 
demonstrates that inadequate antenatal care and monitoring, 
especially in peripheral centers, together play a key role 
in progression to severe disease which culminates in 
eclampsia. Nulliparity as a risk factor for preeclampsia and 
eclampsia was also seen in our study.[17,18] Similar to what 
we found, the advanced gestational age at recruitment in 
severe preeclampsia and eclampsia has been ascribed to the 
occurrence of late‑onset but rapidly progressive disease in 
our environment.[16‑18]
The 14.4% rate of thrombocytopenia we found probably 
reflects the level of coagulopathy complicating preeclampsia 
and eclampsia in our study population, considering that 
only patients with thrombocytopenia had abnormalities of 
the coagulation indices studied. Even so, the 6.7% rate of 
biochemical coagulopathy found in our study is higher than 
Table 3: Pattern of disorders of PT, APTT and plasma fibrinogen 
based on severity of thrombocytopenia






Prolonged PT – 4 (100.0) 2 (22.2) 0.046*
Prolonged APTT – 3 (75.0) – (0.0) 0.014*
Low fibrinogen – 4 (100.0) – (0.0) 0.001*
PT - Prothrombin time; APTT - Activated partial thromboplastin time;* - Statistically 
significant values
Table 4: Contribution of eclampsia to coagulation abnormalities
Variables Severe Pre-eclampsia 
(n=69)
Eclampsia (n=21) P
Eclampsia with Thrombocytopenia 
(n=10)
Eclampsia without Thrombocytopenia 
(n=11)
Platelet count (per µl) 182,000±65846 79400±11596 203,000±65479 0.031*
PT (s) 12.49±1.16 18.80±5.59 12.64±1.57 0.001*
APTT (s) 33.16±2.42 36.40±5.52 33.27±1.56 0.030*
Fibrinogen (g/dl) 3.54±0.26 2.31±0.69 3.47±0.25 0.001*
PT - Prothrombin time; APTT - Activated partial thromboplastin time; * - Statistically significant values
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the 2% reported by Barker et al.,[19] lower than 14.7% reported 
by Sharma et al.[1] but much lower than 50% found by Pritchard 
et al.[3] The varying combinations of coagulation‑fibrinolytic 
indices studied, the peculiarities of the population studied 
as well as the individual predisposition to coagulopathy may 
have significant impact on the results obtained, as well as 
their interpretation; and these may account for the different 
rates between studies.
Similar to what we found, many researchers have reported 
thrombocytopenia to be the most common haemostatic 
abnormality in this group of patients. We found a lower 
rate than the 28% to 50% reported by many previous 
workers.[1‑3,19‑21] Though our figure was higher than 10% 
reported by Riaz et al.,[22] few studies agree with our rate of 
14%.[1,10] This variation is probably explained by the arbitrary 
cut‑off definition of thrombocytopenia adopted by each 
researcher, so that higher rates are expected when a lower 
cut‑off of 100,000 cell/µl is utilised. This understanding will 
seem to suggest that our participants will have a much lower 
thrombocytopenia rate should cut‑off be set at 150,000 cell/µl.
The development of coagulopathy in preeclampsia 
appears to occur early, progressing over the course of the 
disease to involve with varying degrees, the coagulation 
parameters, especially in those with early‑onset disease.[23] 
Thrombocytopenia was predictive of the risk of coagulopathy 
in this study. Biochemical coagulopathy was unlikely at 
platelet count above 88000 cell/µl, however, the rate 
progressively increased for any particular parameter, with 
multiple parameters involvement, as thrombocytopenia 
decreased further below 80000 cell/µl. Abnormal PT was 
common as the mean platelet count started to reduce, 
whereas APTT and fibrinogen abnormalities were noticed at 
lower levels of thrombocytopenia. Thrombocytopenia below 
50000 cell/µl was not found in this study, an observation that 
further suggests the progressive nature of coagulopathy in 
preeclampsia, such that a critical level of reduced platelet 
number and/or function is required to set off the chain 
of events leading to abnormal biochemical coagulopathy. 
Hence, dangerously low values of thrombocytopenia are 
averted by prompt diagnosis and appropriate treatment. 
One of our patients with a platelet count of 68000 cell/µl 
was found to have abnormalities of PT, APTT and fibrinogen 
level and showed clinical evidence of DIC. Aforementioned 
confirms that the more severe the thrombocytopenia, the 
more likely the occurrence of coagulopathy and consequent 
poor prognosis.
The finding that only participants with low platelet 
count were found to have biochemical coagulopathy has 
previously been documented by other workers.[11,12,19] 
Conversely, in a retrospective review of laboratory data 
obtained from 80 patients with hypertensive disorders of 
pregnancy in Pennsylvania, USA, minor abnormalities of 
PT, APTT and fibrinogen level were reported as frequent, 
even in patients with normal platelet count; however, these 
abnormalities were found mostly in patients with severe 
preeclampsia and eclampsia.[24] Prieto et al. also reported 
that no correlation was found between levels of platelet 
count and those of PT, APTT or fibrinogen.[25] However, 
consensus seems to favour the earlier involvement of 
platelets. Hence, it appears safe to monitor platelet count 
initially in the course of management, and to include 
coagulation indices when platelet count level decreases 
below 80000 cell/µl.
Again, our finding that thrombocytopenia occurred 
more when eclampsia supervened had been previously 
documented by Jambhulkar et al.[10] Previous researchers 
have also shown that biochemical coagulopathy appeared 
to be more severe with the development of eclampsia or 
other major complications such as abruptio placentae and 
intrauterine fetal death.[4,8,10,12,23] Our findings also support 
this observation, and this suggests that early determination 
of the risk of coagulopathy and the ongoing evaluation to 
predict disease progression will assist in reducing morbidity 
and mortality contributed by preeclampsia and eclampsia.[26‑29] 
Hence, coagulopathy was increased further in patients who 
had a combination of thrombocytopenia and eclampsia in 
our study.
The factors found to be associated with a significant risk 
of biochemical coagulopathy in preeclampsia in this study 
were severe disease, worsening thrombocytopenia and 
evolution to eclampsia. We also established the relationship 
between thrombocytopenia below 80000 cell/µl and 
the progressive risk and multiple involvements of PT, 
APTT and fibrinogen level abnormalities. To reduce the 
burden of coagulopathy in preeclampsia and eclampsia, 
coagulation studies will be necessary in the evaluation to 
determine the severity and need for correction. However, 
in peripheral settings where facilities may be lacking to 
conduct a coagulation study, assessment of platelet count 
will suffice in detecting significant thrombocytopenia, 
which should then prompt referral to more equipped 
centers.
A larger sample size, prospective case‑control design to 
compare mild preeclampsia with severe preeclampsia, in a 
multicenter collaborative effort will probably improve the 
external validity of the results of our study.
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Conclusion
In conclusion, the critical level of thrombocytopenia 
necessitating coagulation study in severe preeclampsia 
and eclampsia is 80000 cell/µl in our patients. The risk of 
coagulopathy increases with worsening thrombocytopenia 
and development of eclampsia. This will help to identify 
patients who may develop coagulopathy and require 
immediate referral to reduce maternal and perinatal mortality 
and morbidity rates.
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